94
Views
14
CrossRef citations to date
0
Altmetric
LetterToEditor

Acute hepatitis following mycophenolate mofetil administration for ANCA‐positive vasculitis

, , , &
Pages 237-239 | Accepted 05 Jun 2006, Published online: 12 Jul 2009

References

  • Langford C. A., Talar‐Williams C., Sneller M. C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 15:51: 278–83
  • D'Cruz D. P. Mycophenolate mofetil in systemic vasculitis. Lupus 2005; 14: S55–7
  • Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 24; 353: 2219–28
  • Uthman I. Pharmacological therapy of vasculitis: an update. Curr Opin Pharmacol 2004; 4: 177–182
  • Thomas‐Golbanov C., Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10: 1279–89
  • Langford C. A. Management of systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15: 281–97
  • Lee W. M. Drug induced hepatotoxity. N Engl J Med 2003; 349: 474–85
  • Balal M., Demir E., Paydas S., Sertdemir Y., Erken U. Uncommon side effect of MMF in renal transplant recipients. Ren Fail 2005; 27: 591–4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.